Comparison between antiemetic effects of palonosetron and granisetron on chemotherapy-induced nausea and vomiting in Japanese patients treated with R-CHOP

10Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy. The proportions of patients with complete response (CR) during the overall (0-120 h after the start of R-CHOP therapy), acute (0-24 h) and delayed (24-120 h) phases were evaluated. CR was defined as no vomiting and no use of antiemetic rescue medication. A total of 32 and 42 patients were treated with palonosetron and granisetron, respectively. The CR rate in the palonosetron group was significantly higher than that in the granisetron group during the delayed phase (90.6 and 61.9%, respectively; p=0.007). Logistic regression analysis showed that use of palonosetron improved the CR rate during the delayed phase, compared to use of granisetron. Female sex, age less than 60 years, no habitual alcohol intake, and Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 1 were significant risk factors associated with non-CR. The findings of this study suggested the superiority of palonosetron to granisetron, without accompanying dexamethasone and aprepitant, for chemotherapy-induced nausea and vomiting in patients with malignant lymphoma.

References Powered by Scopus

Chemotherapy-induced nausea and vomiting

689Citations
N/AReaders
Get full text

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

458Citations
N/AReaders
Get full text

Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting with Palonosetron, a Pharmacologically Novel 5-HT<inf>3</inf> Receptor Antagonist: Results of a Phase III, Single-Dose Trial Versus Dolasetron

415Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Patient-related risk factors for Chemotherapy-Induced Nausea and Vomiting: A systematic review

71Citations
N/AReaders
Get full text

Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

11Citations
N/AReaders
Get full text

A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Uchida, M., Mori, Y., Nakamura, T., Kato, K., Kamezaki, K., Takenaka, K., … Akashi, K. (2017). Comparison between antiemetic effects of palonosetron and granisetron on chemotherapy-induced nausea and vomiting in Japanese patients treated with R-CHOP. Biological and Pharmaceutical Bulletin, 40(9), 1499–1505. https://doi.org/10.1248/bpb.b17-00318

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

43%

Lecturer / Post doc 4

29%

Professor / Associate Prof. 2

14%

Researcher 2

14%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 4

36%

Medicine and Dentistry 4

36%

Nursing and Health Professions 2

18%

Computer Science 1

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 47

Save time finding and organizing research with Mendeley

Sign up for free